 Celsion Corporation CLSN, a leading oncology drug development company, today jointly announced with Medidata, a Dassault Systèmes company, that examining matched patient data provided by Medidata in a synthetic control arm SCA with results from the Companys completed Phase Ib dose-escalating OVATION 